News for Shanghai Henlius Biotech, Inc. (2696.HK)

Buzzing Stocks Today, Stocks that will see action today: 7 February, 2025 - ITC, Agro Tech Foods, Fortis Healthcare, NTPC Green, Autobindo Pharma, Meson Valves, Solar Industries, Petront LNG, HG Infra, BSE, Zomato, Tata Power, Dr Reddy’s Lab, Mahindra Logistics, Asian Paints

SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's') for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and regions and the United States (U.S.).

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- HR Asia, the leading publication in the human resources industry, announces the winners of its prestigious HR Asia Best Companies to Work for in Asia 2024 - China awards. This year, a total of 43 outstanding companies have been recognized for their exemplary HR practices, showcasing their commitment to fostering a vibrant and diverse workplace environment.

SHANGHAI, China & JERSEY CITY, N.J. — Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the US Food and Drug Administration (FDA) has…

Discover how Fosun has become a global powerhouse with 55% CAGR overseas revenue growth and innovative ventures like Fosun Pharma's international success.

HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available in Europe for first-line treatment of ES- SCLC - HANSIZHUANG (serplulimab) has already been approved in China, Indonesia, Cambodia, and Thailand, benefiting around 80,000 patients SHANGHAI, Sept. 21, 2024 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of HANSIZHUANG (serplulimab), Henlius' independently developed anti-PD-1 monoclonal antibody (mAb), as a first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). In 2023, Henlius entered into an exclusive license agreement with Intas Pharmaceuticals Limited ('Intas') for the development and commercialisation a total of more than 50 countries in Europe and India. This positive opinion from CHMP marks another step closer for both companies to providing serplulimab for patients in Europe. If approved, serplulimab will be marketed by Intas' subsidiary, Accord Healthcare Ltd, in Europe.

EMA accepts HLX14 application from Henlius and Organon

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

SHANGHAI, China & JERSEY CITY, N.J. — Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial…

PI3K inhibitors are primarily used in the treatment of various cancers, including breast cancer, lymphoma, and leukemia. With the global burden of cancer...

The PD-1 and PD-L1 inhibitor market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

/PRNewswire/ -- Allied Market Research published a report, titled, "Biosimilar Monoclonal Antibody Market by Type (Adalimumab, Bevacizumab, Infliximab,...

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA Release...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

The interest of Pharma and the research community in AXL inhibitors as anticancer agents has dramatically increased over the past years. The growing number...

The prevalence of cancer has been rising over the past few years, which prompts the growing demand for treatment options. The introduction of immune...

The introduction of ADCs into the market and the promising clinical results of more ADC prospects have increased industry interest in ADCs as a treatment...